By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
Viking Therapeutics (VKTX) faces significant challenges in commercializing its GLP-1/GIP therapy despite promising near-term catalysts. The panel is divided on its potential as a standalone entity, with some seeing it as a prime acquisition target, while others question its ability to capture market share against established competitors.
Risk: Failure to demonstrate superior phase 3 data compared to existing treatments and the challenge of building a commercial infrastructure to compete with established players.
Opportunity: Potential acquisition by a major pharmaceutical company following successful phase 3 results.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Viking Therapeutics (NASDAQ: VKTX) has seen its stock stumble in recent times -- for example, it's slipped over the past year. But over five years, shares of the biotech company have climbed more than 300%. This is amid excitement about the company's potential in a market that's on track to reach nearly $100 billion in just a few years. I'm talking about the weight loss drug market.
Viking hasn't yet commercialized a drug, but it has a promising candidate in late-stage trials, so it may be very close to the finish line in this valuable market. All of this means the biotech, which specializes in developing candidates for metabolic and endocrine disease, might generate revenue -- and at significant levels -- in just a few years.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Though investors haven't rushed into the stock in recent months, this could soon change. Viking has catalysts just ahead: The company expects to report data from a maintenance dosing study of its weight loss drug candidate in the third quarter, and it aims to launch a phase 3 trial for the oral version of its candidate in the fourth quarter.
Considering this, is Viking stock going to $100? Let's find out.
We'll start with some details about Viking's lead candidate, VK2735. This is an investigational dual GLP-1/GIP receptor agonist, much like the popular drugs sold by market leaders Eli Lilly and Novo Nordisk. These drugs act on hormonal pathways involved in digestion, and as a result, they help control appetite and blood sugar levels. The Lilly and Novo drugs have become blockbusters, and demand has been consistently high for these products -- this is thanks to their efficacy, safety, and ease of use.
Though these pharma giants dominate the space, as mentioned, it is a high-growth market, so there is room for others to enter. And even if a company such as Viking doesn't take leadership -- and I wouldn't expect it to unseat a massive pharma company like Lilly or Novo -- it still could bring in blockbuster revenue. That could be quite a huge step for a young biotech.
And Viking does offer its own twist, differentiating itself from current GLP-1 drugs. At the moment, Lilly offers a dual GLP-1/GIP drug in injectable format and a GLP-1 drug in oral format. Novo's obesity drugs are GLP-1s. (Dual GLP-1/GIP drugs interact with two hormonal pathways, while GLP-1s interact with only one hormonal pathway.)
Viking is developing VK2735 in both injectable and oral formats. So, if approved, it would be the first dual GLP-1/GIP drug available in oral format -- and the first dual available in both injectable and oral formats. One big advantage of this is that patients can shift from one formulation to the other -- for example, starting with the oral treatment and then using the injectable for maintenance once they've reached their desired weight.
The phase 3 trial for Viking's injectable is ongoing, and as mentioned, the phase 3 study for the oral formulation is set to begin later this year. We also should see data from its maintenance dosing trial in the months to come. These events could represent catalysts for the stock, which has been known to react to news. When Viking initially announced phase 2 data for VK2735 a couple of years ago, the stock soared more than 100% in one trading session.
So now, let's return to our question: Is Viking heading to $100? It reached a high of more than $94 when it announced phase 2 data in February of 2024. The stock has since given back much of that gain, and it trades today for about $27. But the average Wall Street estimate calls for it to reach more than $92 within the coming 12 months, recovering much of that territory.
The path to $100 represents a jump of more than 200%. I don't see that happening overnight like Viking's massive gain in February of 2024. But a few updates or general good news in the obesity drug market could help it along the way -- so Viking could indeed be heading to $100 in the quarters to come.
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $442,220! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,230,114!
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of June 12, 2026. *
Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"VK2735 could unlock meaningful upside if phase 3 data are positive and the oral+injectable dual edge proves durable, but without revenue and amid competition and regulatory risk, the upside is far from guaranteed."
This article leans bullish on Viking Therapeutics (VKTX) on near‑term catalysts (maintenance dosing readout in Q3 and an oral phase 3 launch in Q4) and the potential of a dual GLP‑1/GIP therapy. The strongest caveat: Viking has no approved product and must win multi‑billion‑dollar market adoption against Lilly/Novo. Even robust phase 3 data may not translate into revenue if safety issues arise, trials face delays, or payer coverage proves restrictive. The “oral + injectable” edge is unproven, and the company still lacks a commercialization plan and scale. The implied 12‑month target (~$92) assumes rapid revenue, which is far from assured.
Even with clean phase 3 data, achieving a $92+ price tag hinges on revenue windfalls in a crowded market; a regulatory setback or weaker adoption could erase upside quickly.
"The stock's path to $100 depends entirely on a successful buyout or a 'best-in-class' clinical readout, as Viking lacks the operational scale to compete independently against incumbents."
Viking Therapeutics (VKTX) is currently a binary play on clinical execution, not a value investment. While the $100 price target cited by the article reflects the market's 'blue sky' potential for VK2735, it ignores the brutal reality of commercialization. Viking lacks the massive sales force, manufacturing scale, and supply chain infrastructure that Eli Lilly (LLY) and Novo Nordisk (NVO) have spent decades building. Even with superior clinical data, Viking faces a daunting 'go-to-market' hurdle. Investors are pricing in a buyout premium, but if the phase 3 data fails to show a clear 'best-in-class' profile versus Zepbound or Wegovy, the stock could easily retest its sub-$20 support levels.
If Viking’s oral formulation demonstrates superior tolerability and comparable efficacy to existing injectables, it could capture significant market share via a licensing deal with a major pharma player, rendering their lack of infrastructure irrelevant.
"VKTX is priced for near-term phase 3 success; any stumble or modest efficacy data triggers 30-50% downside, while upside requires not just approval but meaningful market penetration against entrenched competitors."
Viking's $100 target rests entirely on VK2735 phase 3 success and oral formulation approval—neither guaranteed. The article conflates market size ($100B obesity space) with Viking's addressable share, a common biotech trap. At $27, VKTX is priced for meaningful approval odds, but the stock already jumped 300% over five years and 100%+ on phase 2 data. Lilly and Novo have entrenched distribution, insurance formularies, and real-world efficacy data. Viking's oral dual agonist is differentiated, but differentiation ≠ market share. Phase 3 failure or modest efficacy data could halve the stock. The article's Wall Street $92 target (12-month) is speculative consensus, not fundamental analysis.
If VK2735 oral shows superior weight loss or tolerability in phase 3, and insurance covers it faster than Lilly's oral tirzepatide, Viking could capture 5-10% of a $50B+ obesity market by 2028—easily justifying $100+. The dual GLP-1/GIP mechanism is genuinely harder to replicate than single-pathway drugs.
"VKTX faces binary clinical and dilution risks that make a sustained move to $100 improbable without flawless execution the article ignores."
VKTX trades at a speculative premium on VK2735's dual GLP-1/GIP mechanism and upcoming phase 3 catalysts, yet the article downplays binary trial risk and the fact that Lilly and Novo already control the market with approved products generating tens of billions. Pre-revenue biotechs routinely dilute shareholders; VKTX has no commercial infrastructure and faces potential safety or efficacy shortfalls that could reset valuation below current levels near $27. The $100 scenario requires not just approval but outsized market share capture within a crowded field.
Positive maintenance data in Q3 or clean phase 3 initiation could still trigger another 100% spike like February 2024 regardless of long-term competitive odds.
"Licensing deals may cap upside and shift commercialization risk, making VKTX's path to a meaningful 2028 obesity market slower and less certain than implied by the 'license-ready' thesis."
Gemini's emphasis on licensing as a path to scale assumes upside is preserved; in reality, partnerships often cap revenue, include milestone traps, and transfer commercialization risk to a partner. If VK2735 needs a buy-in or license, the stock isn't pricing in the risk of slower adoption or onerous royalties. The real test isn't Phase 3 data alone but whether any deal preserves meaningful, timely access to a $50B obesity market by 2028.
"Viking's primary value driver is its acquisition potential by late-to-market pharma majors rather than its ability to build an independent commercial infrastructure."
Claude and Gemini are fixated on commercialization, but they ignore the M&A reality: VKTX is a prime acquisition target for Big Pharma players like Pfizer or Amgen that missed the initial GLP-1 boat. Whether Viking builds a sales force is irrelevant if they are bought out at a 40% premium post-Phase 3. The risk isn't 'market share'—it's the binary clinical outcome that determines if they are a buyout candidate or a bankrupt shell.
"M&A as a de facto exit assumes Big Pharma will pay premium valuations for clinical-stage dual agonists; current biotech market discipline and Lilly/Novo's entrenched position make that assumption fragile."
Gemini's M&A thesis assumes Big Pharma overpays for clinical-stage assets—true historically, but post-2022 biotech valuations have compressed sharply. Pfizer and Amgen aren't desperate; they're disciplined. A $5–8B acquisition price (40% premium to current market cap) requires VKTX to prove phase 3 superiority *and* manufacturing feasibility. If data is merely 'non-inferior' to Zepbound, the buyout premium evaporates. Gemini conflates acquisition *probability* with acquisition *inevitability*—a critical distinction when phase 3 is still months away.
"Dilution and manufacturing shortfalls make a premium buyout far less assured than claimed."
Gemini's M&A thesis skips the cash-burn reality: Viking will likely dilute shares multiple times before phase 3 data arrives in 2026, shrinking any future premium. Acquirers won't ignore manufacturing gaps or the need for superiority versus Lilly's pipeline; a merely adequate dataset leaves the company exposed to lowball offers or no deal at all, resetting the stock well below current levels.
Viking Therapeutics (VKTX) faces significant challenges in commercializing its GLP-1/GIP therapy despite promising near-term catalysts. The panel is divided on its potential as a standalone entity, with some seeing it as a prime acquisition target, while others question its ability to capture market share against established competitors.
Potential acquisition by a major pharmaceutical company following successful phase 3 results.
Failure to demonstrate superior phase 3 data compared to existing treatments and the challenge of building a commercial infrastructure to compete with established players.